Single-dose neonatal gene therapy preserves motor coordination and extends survival of Polg-deficient mice
This study demonstrates that a single-dose neonatal gene therapy using AAV vectors successfully preserves motor coordination and extends survival in a newly developed Polg-deficient mouse model, providing preclinical proof of concept for treating POLG-related mitochondrial diseases.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Mitochondria are the tiny power plants inside nearly every cell of the human body, generating the energy required for life. To keep these power plants running, cells rely on a specific set of instructions stored in a small, separate circle of genetic material called mitochondrial DNA. However, this DNA is fragile and requires a specialized molecular machine to copy and repair it. This machine is built by a gene called POLG. When the POLG gene is damaged, the machinery fails, the power plants run out of instructions, and the cells begin to shut down. This failure causes a group of severe conditions known as mitochondrial diseases, which can strike at any age but are often most devastating in infants, leading to liver failure, seizures, and early death. For decades, there has been no cure for these conditions, only treatments that manage symptoms without stopping the underlying decline. The central challenge for scientists trying to fix this has been twofold: the genetic instructions needed to rebuild the broken machine are too large to fit inside the tiny delivery vehicles usually used for gene therapy, and there has been no reliable animal model that accurately mimics the rapid, fatal progression seen in human patients.
Researchers at the Imagine Institute in Paris and The Jackson Laboratory have now taken a significant step toward overcoming these hurdles. They developed a new type of mouse that carries a broken POLG gene specifically in the parts of the brain responsible for movement and in certain fast-moving muscle fibers. Unlike previous mouse models that lived relatively normal lives, these new mice began to show signs of trouble as they grew. They started to lose their balance, developed tremors, and struggled to walk, eventually dying prematurely. This behavior closely mirrors the severe, early-onset forms of POLG disease seen in children. By creating this model, the team established a realistic testbed to see if they could stop the disease before it destroyed the animal.
With the mouse model ready, the team turned to the problem of delivery. They designed nine different versions of a gene therapy vector, which is a harmless virus engineered to carry healthy genetic instructions into cells. Because the POLG gene is too big to fit into a standard viral package, the scientists had to strip away unnecessary parts of the virus's own genetic code to make room. They tested these nine designs in the lab and found that they could successfully deliver the healthy gene into various tissues, including the brain, heart, and liver. The virus acted like a courier, entering the cells and instructing them to build the missing protein needed to repair the mitochondrial power plants.
The most critical test involved treating newborn mice that were genetically programmed to develop the disease. The researchers injected a single, high dose of the most promising viral vectors into the tiny temporal vein of the newborns, a route that allows the virus to spread quickly throughout the body, including the brain. The results were striking. While the untreated mice began to fail within a few months, the treated mice remained healthy. They maintained their ability to walk and balance, and they lived significantly longer. In fact, most of the treated mice survived well past the point where the untreated animals had already died. When the scientists examined the brains and muscles of the treated mice, they found that the cells were still producing the healthy protein, the mitochondrial power plants were functioning, and the genetic instructions for energy production were intact.
This work does not yet mean the disease is cured for humans, but it provides the first strong evidence that a gene therapy approach is possible for POLG disease. The study demonstrates that it is technically feasible to package the large genetic instructions needed for this repair and deliver them to the right places in the body. It also proves that intervening very early, while the cells are still healthy, can prevent the catastrophic failure that leads to death. The researchers noted that their success relied on treating the mice before symptoms appeared, suggesting that timing is crucial. While questions remain about how to handle patients who are already sick or how to manage the immune system's reaction to the virus, this study lays a solid foundation. It shows that the path to a potential cure is not blocked by the size of the gene or the lack of a good model, and it offers a concrete strategy for moving forward with the development of a treatment that could one day save lives.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.